CN100554247C - 毒蕈碱激动剂 - Google Patents

毒蕈碱激动剂 Download PDF

Info

Publication number
CN100554247C
CN100554247C CNB038192500A CN03819250A CN100554247C CN 100554247 C CN100554247 C CN 100554247C CN B038192500 A CNB038192500 A CN B038192500A CN 03819250 A CN03819250 A CN 03819250A CN 100554247 C CN100554247 C CN 100554247C
Authority
CN
China
Prior art keywords
methylamino
carboxylic acid
treatment
fluorobenzyl
ethyleneamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038192500A
Other languages
English (en)
Chinese (zh)
Other versions
CN1675173A (zh
Inventor
J·K·布什
P·C·赫思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1675173A publication Critical patent/CN1675173A/zh
Application granted granted Critical
Publication of CN100554247C publication Critical patent/CN100554247C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB038192500A 2002-08-22 2003-08-12 毒蕈碱激动剂 Expired - Fee Related CN100554247C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40544302P 2002-08-22 2002-08-22
US60/405,443 2002-08-22

Publications (2)

Publication Number Publication Date
CN1675173A CN1675173A (zh) 2005-09-28
CN100554247C true CN100554247C (zh) 2009-10-28

Family

ID=31946873

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038192500A Expired - Fee Related CN100554247C (zh) 2002-08-22 2003-08-12 毒蕈碱激动剂

Country Status (19)

Country Link
US (1) US7160922B2 (https=)
EP (1) EP1534667B1 (https=)
JP (1) JP4469280B2 (https=)
CN (1) CN100554247C (https=)
AR (1) AR040889A1 (https=)
AT (1) ATE491683T1 (https=)
AU (1) AU2003256791B2 (https=)
BR (1) BR0313161A (https=)
CA (1) CA2493958C (https=)
CY (1) CY1111115T1 (https=)
DE (1) DE60335380D1 (https=)
DK (1) DK1534667T3 (https=)
ES (1) ES2355213T3 (https=)
MX (1) MXPA05002080A (https=)
PE (1) PE20040894A1 (https=)
PT (1) PT1534667E (https=)
SI (1) SI1534667T1 (https=)
TW (1) TW200410922A (https=)
WO (1) WO2004018411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275095A3 (en) * 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2013523679A (ja) 2010-03-29 2013-06-17 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌性イミノ誘導体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027061A2 (en) * 2001-09-21 2003-04-03 Eli Lilly And Company Muscarinic agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027061A2 (en) * 2001-09-21 2003-04-03 Eli Lilly And Company Muscarinic agonists

Also Published As

Publication number Publication date
CA2493958A1 (en) 2004-03-04
WO2004018411A1 (en) 2004-03-04
CN1675173A (zh) 2005-09-28
BR0313161A (pt) 2005-06-14
ES2355213T3 (es) 2011-03-23
CY1111115T1 (el) 2015-06-11
JP2005536549A (ja) 2005-12-02
MXPA05002080A (es) 2005-08-18
PE20040894A1 (es) 2004-11-25
AR040889A1 (es) 2005-04-20
DK1534667T3 (da) 2011-02-14
DE60335380D1 (de) 2011-01-27
US7160922B2 (en) 2007-01-09
TW200410922A (en) 2004-07-01
EP1534667B1 (en) 2010-12-15
JP4469280B2 (ja) 2010-05-26
EP1534667A1 (en) 2005-06-01
AU2003256791A1 (en) 2004-03-11
ATE491683T1 (de) 2011-01-15
AU2003256791B2 (en) 2008-12-11
US20060122280A1 (en) 2006-06-08
CA2493958C (en) 2010-11-09
SI1534667T1 (sl) 2011-02-28
PT1534667E (pt) 2011-01-19

Similar Documents

Publication Publication Date Title
EP2064192B1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
WO2019085933A1 (zh) 作为Wee1抑制剂的大环类化合物及其应用
WO2004022538A1 (ja) 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬
KR20180015259A (ko) Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
JP2007520440A (ja) ムスカリン性受容体アゴニストとしてのインダン誘導体
CN109516989A (zh) 一类抑制并降解cdk的化合物
WO2018171816A1 (zh) 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途
CN100516047C (zh) 内酰胺化合物
TW202334149A (zh) 製備具有經取代之苯基或吡啶基部分的 serd 三環化合物的方法
EP3981768A1 (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
EP4273143B1 (en) Derivative of 2,5-diketopiperazine compound, and preparation method therefor, pharmaceutical composition thereof and use thereof
EA009981B1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
CN101896477B (zh) 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
EP3902545B1 (en) Novel salts of selective estrogen receptor degraders
CN100554247C (zh) 毒蕈碱激动剂
CN110753691A (zh) 化合物
JPH10506111A (ja) タモキシフェンおよびタモキシフェン類縁体の向子宮効果を削減する方法
CN104650109A (zh) 紫杉烷类化合物
JP2005538031A (ja) ラクタム化合物
CN118047708A (zh) 一种二肽基肽酶iv抑制剂的晶型及其制备方法和用途
JPH09508917A (ja) フェニルピロール誘導体およびそのドーパミンｄ▲下３▼アンタゴニストとしての使用
CN102666528A (zh) 晶体cdc7 抑制剂盐
RU2783243C2 (ru) Макроциклическое соединение, выполняющее функции ингибитора wee1, и варианты его применения
HK40022857B (zh) 用於治疗性和/或预防性治疗癌症的化合物
JP2003514807A (ja) 固態形の５−［［６−［（２−フルオロフェニル）メトキシ］−２−ナフタレニル］メチル］−２，４−チアゾリジンジオン

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091028

Termination date: 20130812